Cosmo Pharmaceuticals N.V.
CMOPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $153,367 | $1,532 | $24,473 | $24,003 |
| Dep. & Amort. | $12,285 | $14,261 | $13,856 | $7,369 |
| Deferred Tax | $0 | $0 | $0 | -$21,360 |
| Stock-Based Comp. | $2,074 | $3,826 | $2,077 | $1,457 |
| Change in WC | $113 | $946 | -$13,314 | -$5,072 |
| Other Non-Cash | -$5,428 | $2,143 | $6,134 | $6,214 |
| Operating Cash Flow | $162,411 | $22,708 | $33,226 | $12,611 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$4,552 | -$3,347 | -$7,310 | -$8,504 |
| Net Acquisitions | $0 | $0 | $0 | $23,337 |
| Inv. Purchases | -$157,364 | -$60,956 | -$54,049 | -$1,002 |
| Inv. Sales/Matur. | $33,910 | $117,739 | $35,915 | $7,737 |
| Other Inv. Act. | -$875 | -$11,133 | $27,133 | $3,289 |
| Investing Cash Flow | -$128,881 | $42,303 | $1,689 | $24,857 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$1,076 | -$176,028 | -$916 | -$2,624 |
| Stock Issued | $3,377 | $687 | $270 | $761 |
| Stock Repurch. | -$5,931 | -$12,475 | -$24,747 | -$20,506 |
| Dividends Paid | -$32,094 | -$16,890 | -$15,607 | $0 |
| Other Fin. Act. | -$4,500 | -$6,560 | -$5,133 | -$4,878 |
| Financing Cash Flow | -$40,224 | -$211,266 | -$46,133 | -$27,247 |
| Forex Effect | $715 | -$210 | -$1,517 | $2,402 |
| Net Chg. in Cash | -$5,979 | -$135,550 | -$12,735 | $12,623 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $50,275 | $185,825 | $198,560 | $185,937 |
| End Cash | $44,296 | $50,275 | $185,825 | $198,560 |
| Free Cash Flow | $156,758 | $18,312 | $25,916 | $4,107 |